Lastacaft (alcaftadine) / J&J, AbbVie - LARVOL DELTA

Treatment of allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis. (PubMed, Postepy Dermatol Alergol) - "These two groups had similar incidence of adverse events (OR = 0.61; 95% CI = 0.34 to 1.09; p = 0.10). Alcaftadine had better capability to treat allergic conjunctivitis compared to olopatadine."

Journal • Retrospective data • Review • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Cutaneous Calcium/Calmodulin-Dependent Protein Kinase II-γ-Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis. (PubMed, Adv Sci (Weinh)) - "Application of alcaftadine, a small-molecule CaMK2γ inhibitor, relieves imiquimod-induced psoriasis-like manifestations in mice. This study reveals the mechanisms of sympathetic-nervous-system regulation of γδT-cell interleukin-17 secretion, and provides insight into neuropsychiatric factors dictating psoriasis pathogenesis and new potential targets for clinical psoriasis treatment."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Psychiatry • IL17A

Determination of antihistaminic drugs alcaftadine and olopatadine hydrochloride via ion-pairing with eosin Y as a spectrofluorimetric and spectrophotometric probe: application to dosage forms. (PubMed, BMC Chem) - "Beer's law was obeyed in the concentrations range of 0.8-8.0 and 1.0-10.0 µg mL-1. The four techniques were evaluated in accordance with ICH requirements and were effectively used to analyze dosage forms with a high percent recovery."

Journal

Spectrophotometric platform windows' exploitation for the green determination of Alcaftadine in presence of its oxidative degradation product. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Statistical comparisons were done between the proposed methods and the reported one showing no significant difference concerning accuracy and precision. Furthermore, greenness profile assessment was accomplished by means of four metric tools; namely: analytical greenness (AGREE), green analytical procedure index (GAPI), analytical eco-scale, and national environmental method index (NEMI)."

Journal

Novel solid-contact ion-selective electrode based on a polyaniline transducer layer for determination of alcaftadine in biological fluid. (PubMed, RSC Adv) - "Additionally, the sensor was capable of quantifying the studied drug in a rabbit aqueous humor. Method's greenness profile was evaluated by the means of Analytical Greenness (AGREE) metric assessment tool."

Journal

Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists. (PubMed, Indian J Ophthalmol) - "Respondents were asked about the newer molecule (alcaftadine) and reservations regarding systemic immuno-suppressants and ordering allergy tests in their practice...The signs and symptoms can vary from subtle, innocuous forms to devastating variants affecting vision and day-to-day work. This survey aims to elicit responses from clinicians spreading across different geographical areas and compares responses based on experience in practice."

Journal • Allergy • Conjunctivitis • Dry Eye Disease • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

"#CHCNewsflash: #Lastacaft alcaftadine ophthalmic 0.25% solution (@allerganeye #Allergan / @abbvie #AbbVie) is now available without a prescription online and in retail stores for individuals aged 2+ years with ocular allergies." (@NicholasHallCo)

Allergy • Immunology • Ophthalmology

"$ABBV Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours https://t.co/55tqBpI0oM" (@stock_titan)

Allergy • Immunology

Stability-indicating UPLC, TLC-densitometric and UV-spectrophotometric methods for alcaftadine determination. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "The proposed methods were successful for quantitation of alcaftadine in ophthalmic solution and in plasma samples. The obtained results were in accordance with those obtained by previously reported methods."

Journal • Ophthalmology

Development of allergic conjunctivitis induced by Acanthamoeba excretory-secretory protein and the effect of resolvin D1 on treatment. (PubMed, Curr Eye Res) - "Then, the treatment effects of RvD1 and the antiallergic agents (olopatadine, bepotastine, and alcaftadine) on the HCVCs, mouse conjunctivas, dLNs, and spleens were assessed. All findings were significantly decreased upon treatment with RvD1 and the antiallergic agents. Acanthamoeba could be used to establish an animal model of AC, which could be effectively treated with RvD1 or topical antiallergic agents."

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13 • IL4 • IL5

Drugs for allergic rhinitis and allergic conjunctivitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis. (PubMed, Indian J Ophthalmol) - "All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergic conjunctivitis."

Clinical • Journal • Conjunctivitis • Ocular Inflammation • Ophthalmology

Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study. (PubMed, Ocul Immunol Inflamm) - "Once-daily Alcaftadine 0.25% is safe and effective in preventing signs and symptoms of Japanese cedar-pollen allergic conjunctivitis."

Clinical • Journal • P3 data • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy (clinicaltrials.gov) - P4; N=12; Active, not recruiting; Sponsor: ORA, Inc.

New P4 trial • Biosimilar • Hematological Malignancies • Immunology • Inflammation

Allergic conjunctivitis identified by symptomatic giveaways (Healio) - "Patients who complain of itchiness...for a diagnosis of allergic conjunctivitis, Melissa Toyos...told Ocular Surgery News...'Allergy skin testing, such as Doctor Rx’s Allergy Formula (Bausch + Lomb), can be performed to aid the clinician in diagnosing ocular surface disease, when to treat allergies and what allergens to avoid. The company’s tests are designed precisely for each area of the country and its allergic triggers. The test takes about 20 minutes and is performed by a technician with a physician in the building,' Epitropoulos said."

Media quote

Comfort Comparison of Once-A-Day Anti-Allergy Ophthalmic Meds (AAOPT 2016) - "Purpose: This study compares the differences in perceived ocular comfort of three distinct once-a-day, dual-action anti-allergy prescription medications: 0.25% alcaftadine (Lastacaft), olopatadine hydrochloride 0.2% (Pataday), and olopatadine hydrochloride 0.7% (Pazeo). While, at 24 hrs after dosing, the more concentrated O.7% olopatadine solution reportedly improves relief of ocular itching compared to the O.2% olopatadine sol., the perceived ocular comfort on instillation has not been decreased for subjects aged either under or the over 40. In addition to comfort, the convenient once-a-day dosing impacts patient compliance with all ophthalmic dosing regimens."

Clinical • Biosimilar • Immunology • Ophthalmology

"Não acredito que paguei R$ 57,00 em 3ml de lastacaft @Allergan" (@dgobatista)

Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. (PubMed, BMC Ophthalmol) - "Alcaftadine seems to have less side effects and better therapeutic effects than the other two anti-allergic agents tested. It may be more beneficial to use less toxic agents for patients with ocular surface risk factors or presumed symptoms of toxicity."

Journal

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. (PubMed, Indian J Ophthalmol) - "Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis."

Clinical • Journal

Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. (PubMed, Ocul Immunol Inflamm) - "Alcaftadine 0.25% is effective in preventing signs and symptoms of Japanese cedar pollen-induced allergic conjunctivitis."

Clinical • Journal

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report. (PubMed, BMC Ophthalmol) - "Although there have been no previous reports of alcaftadine 0.25%-associated ACD, it should be suspected in patients with swelling and erythematous change of both eyes after using alcaftadine 0.25%."

Clinical • Journal

Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. (PubMed, Curr Opin Allergy Clin Immunol) - "The topical dual-action agents are the most effective agents treating signs and symptoms of mild forms of AC. There is superiority to the high-concentration olopatadine drug over other agents on ocular itch, with prolonged effect when used once-daily."

Journal

A comparative study of cellular cytotoxicity on the corneal epithelial cells and allergic cytokines production on the conjunctival cells by the dual-action anti-allergic eye drops (ESCRS-WM 2019) - "Alcaftadine 0.25% seems to have less side effects of cytotoxicity, and better inhibition of allergic cytokines than bepotastine besilate 1.5% and olopatadine HCL 0.1%. It may be more beneficial to use less toxic agents for allergic patients with ocular surface disorder or presumed symptoms of toxicity."